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Abstract 
Non-enzyme dependent hydrolysis of the drug cisplatin is important for its mode of action 
and toxicity. However, up until today, the hydrolysis process of cisplatin is still not 
completely understood. In the present study, the hydrolysis of cisplatin in an aqueous 
solution was systematically investigated using electrospray ionization mass spectrometry 
coupled to liquid chromatography. A variety of previously unreported hydrolysis complexes 
corresponding to mono-, di-, and trimeric species were detected and identified. The 
characteristics of the Pt-containing complexes were investigated using collision induced 
dissociation (CID). The hydrolysis complexes demonstrate distinctive and correlative CID 
characteristics, which provides tools for an informative identification. The most frequently 
observed dissociation mechanism was sequential loss of NH3, H2O, and HCl. Loss of the Pt 
atom was observed as the final step during the CID process. The formation mechanisms of 
the observed complexes were explored and experimentally examined. The strongly bound 
dimeric species, which existed in solution, are assumed to be formed from the clustering of 
the parent compound and its mono- or dihydrated complexes. The role of the electrospray 
process in the formation of some of the observed ions was also evaluated and the ESI 
related cold clusters were identified. The previously reported hydrolysis equilibria were 
tested and subsequently refined via a hydrolysis study resulting in a renewed mechanistic 

















Platinum complexes are a major class of chemotherapeutic agents against cancer[1, 2], with 
cisplatin (cis-diamminedichloroplatinum (II)), carboplatin (cis-diammine 1,1-cyclobutane 
dicarboxylato platinum (II)), oxaliplatin (1R, 2R -diaminocyclohexane) oxalatoplatinum (II)), 
and nedaplatin (cis-diammine-glycolatoplatinum (II)) being first-line representatives used for 
the treatment of a wide variety of cancers such as ovarian and testicular carcinomas[3-7]. 
Even though the platinum complexes have been widely used for cancer therapies since the 
first member cisplatin was discovered in the 1960s[8], the mechanisms of action and toxicity 
for these coordination complexes are still not completely understood[5, 9, 10]. It is generally 
accepted that the mode of action of platinum complexes consists of binding of the 
hydrolyzed complexes to the DNA. This requires activation through non-enzyme dependent 
hydrolysis. Through this binding to the DNA and reaction with other biologically important 
molecules[7, 8, 11, 12], they exert an anticancer activity but also cause undesirable side effects 
such as cytotoxicity and nephrotoxicity[8, 13, 14]. Therefore, understanding the hydrolysis 
process of platinum complexes is of considerable significance to elucidate  the mechanisms 
behind the anticancer and toxic effects and also to pave the way for the development of new 
coordination complexes in the fight against cancer.  
The hydrolysis of cisplatin has previously been explored through various types of 
conventional techniques such as HPLC-UV, atomic absorption spectrometry (AAS), flame 
atomic absorption spectroscopy (FAAS), X-ray, electrochemical detection, inductively 
coupled plasma-mass spectrometry (ICP-MS), HPLC-ICP-MS, and nuclear magnetic resonance 
(NMR)[15-17]. A schematic overview of the different hydrolysis products of cisplatin in water is 
summarized in Figure 1[10, 18, 19]. Some of the aforementioned techniques cannot 
differentiate parent drug and its hydrolysis species since they only measure total platinum. A 
typical example of this is presented by Hann et al. who reported on a detailed hydrolysis 
speciation of cisplatin via HPLC-ICP-MS[20]. In this study, large amounts of unknown Pt-
species were found in the hydrolysis solution along with cisplatin, and its monohydrated 
complex (MHC) and dihydrated complex (DHC). Furthermore, only NMR spectrometry can 
provide definitive structural information on cisplatin and its hydrolysis products[6, 21]. 
However, in order to obtain NMR spectra, at least high microgram to milligram amounts of 
material are required[6, 10]. For platinum complexes which are almost insoluble in most 
organic solvents (e.g. methanol and acetonitrile) and are not stable in aqueous solution[22], 
this is very challenging. In addition to this, relatively pure samples of target compounds are 
often required for these techniques, which makes the reliable detection of these unstable 
complexes even more challenging. Due to these limitations, up until today, the hydrolysis 
scheme of cisplatin is still not completely clarified[20]. Therefore, it is worthwhile to 
experimentally re-examine the reported hydrolysis process using a technique which is able 
to provide structural information such as electrospray ionization mass spectrometry (ESI-
MS).   
ESI-MS is a powerful and versatile technique for structural identification of metal-containing 
aqueous solutions. A variety of platinum and palladium complexes containing various ligands 
have been previously investigated using ESI-MS[23-25]. Nevertheless, only limited mass 
spectral data regarding the hydrolysis of cisplatin is available in the literature[10, 18]. Ehrsson 
and coworkers[18] were the first to study the characteristics of cisplatin in water using ESI-
MS. They identified the sodium adduct of cisplatin, and proton and acetonitrile-adducts of 
the mono- and dihydrated products. In this study, the spectra were recorded in a relatively 
narrow mass range m/z 10 - 500, and only limited full scan spectra and fragmentation 
information was used for the identification. M. Cui et al. reported a detailed ESI-MS 
spectrum as well as a fragmentation pathway of cisplatin and its hydrated complexes[10]. A 
hydroxo-bridged dimer of the dihydrated species was identified in their study. However, 
three abundant species located at the range of m/z 500 - 580 in the full scan ESI mass 
spectrum were left unidentified.  
It should be noted that the oligomeric complexes observed via ESI-MS are not always a true  
reflection of the composition of the species in solution. Sometimes cold clusters are 
produced in the electrospray process. This is most likely to occur when an electrosprayed 
solution contains neutral as well as charged species[5, 26]. Therefore, care should be taken 
when an oligomer is found and additional efforts should be devoted to elucidate whether 
such an oligomer is produced in the solution or is actually a cold  cluster of the ESI-MS 
process.  
The above mentioned difficulties are overcome when ESI-MS is hyphenated with the 
resolving power of an LC system. Then, it is possible to elucidate what ESI-MS species are 
formed, and where (i.e. in solution or gas phase or both) and how they are formed. The in-
depth understanding of the aqueous chemistry of cisplatin contributes to the general 
knowledge of the hydrolysis process of platinum (II) and potentially also palladium(II) 
complexes for which cisplatin could be regarded as a model compound.  
The goal of present study was to 1) provide a comprehensive and thorough understanding of 
the hydrolysis process of cisplatin and identify all hydrolysis products; 2) generate kinetic 





Cisplatin was purchased from the EDQM Council of Europe. ULC-MS grade water and 
isopropanol were obtained from Biosolve (Valkenswaard, The Netherlands). Formic acid and 
ammonium formate were supplied from Sigma-Aldrich (Belgium).  
 
Hydrolysis of cisplatin 
The stock solution (± 1 mM, pH 5.85) was freshly prepared by dissolving approximately 3.0 
mg cisplatin in 10.0 mL of ULC-MS water with a resistivity of 18.2 - 30 Mohm·cm. The bottle 
was closed and heated to 37 °C in an oven. Aliquots were removed from this solution at pre-
defined time points according to the purpose of study. For the ESI-MS infusion study, 
aliquots were taken from the solution at 0, 4, 24, and 72 h. These solutions were diluted 5-
fold with ULC-MS water prior to infusion. For UPLC-ESI-MS/MS experiments, the aliquots 
were taken at 0, 0.5, 1, 2, 3, 4, 5, 7, 24, 27, 30, 48, and 55 h. These samples were 
immediately stored at -80 °C until analysis. Afterwards the samples were allowed to thaw 
and were diluted 10-fold with ULC-MS water and subsequently 4-fold with acetone prior to 
injection onto the UPLC system. 
 
Liquid chromatography 
Chromatographic separations were performed on a Syncronis HILIC column (50 x 2.1 mm, 
1.7 µm, Fisher Scientific, Aalst, Belgium) installed on an Acquity UPLC H-class system 
(Waters, Milford, MA). The mobile phase (MP) consisted of MP A (10/85/5 
isopropanol/water/100 mM ammonium formate buffer, pH 2.75) and MP B (95/5 
isopropanol /100 mM ammonium formate buffer, pH 2.75). Components were eluted using a 
linear gradient at a flow rate of 0.4 mL/min which consisted of the following sequence: 0-3.0 
min, from 95% MP B to 60% MP B; 3.0-3.5 min, from 60% MP B to 95% MP B; 3.5-5.5 min, 
95% MP B. The column temperature was maintained at 45 °C, and the injection volume was 
2 μL.  
 
Mass spectrometry 
All MS experiments were performed using a Waters Xevo TQS tandem mass spectrometer 
(Waters, Milford, MA) operated in positive electrospray ionization (ESI+) mode. The 
desolvation gas (nitrogen) flow rate was set to 1000 L/h at a temperature of 500 °C, and 
collision gas (argon) flow was maintained at 0.15 mL/min. The source temperature was 
maintained at 125°C. For ESI-MS experiments, all data were collected and analyzed using 
Masslynx 4.1 software using MS scan (full scan) and MS/MS modes. The MS scan spectra 
were acquired in the mass range of 100 - 1000 m/z for 2.0 mins. The electrospray capillary 
voltage and cone voltage were optimized at 3.0 kV and 20 V, respectively, to maintain 
satisfactory sensitivity and circumvent in-source fragmentation. The collision energy (CE) 
used for the collision-induced dissociation (CID) was tested on a low, medium, and high 
setting (4-70 eV) for each species. The aqueous solutions were introduced to the source at a 
flow rate of 20 µL/min. For LC-ESI-MS/MS experiments, the hydrolysis complexes were 
detected in multiple reaction monitoring (MRM) mode with a dwell time of 0.020 s per 
transition. Details of the optimized MRM transitions and parameters for each species are 
presented in Table 1.  
 
Results and discussion 
ESI-MS scan and CID experiments 
Hydrolysis complexes containing different numbers of platinum and chloride atoms are fairly 
straightforwardly distinguished via ESI-MS due to the naturally occurring stable isotopes of 
platinum and chloride. The isotopic distribution for platinum starts at 190.0 Da (0.014 %) and 
continues up to 198.0 Da (7.16 %) with the most abundant mass at 195.0 Da (33.83 %). 
Chloride gives two abundant isotopes at 35.0 Da (75.78 %) and 37.0 Da (24.22 %). The 
theoretical isotope distributions for molecules containing PtnCln elements are summarized in 
supplementary Table S1. The identification of the observed parent and product ions 
containing Pt and Cl elements is achieved through the comparison of the experimentally 
observed isotopic clusters with the calculated expected isotope cluster patterns by using the 
windows-based IsoPatrn program[27]. In this study, the mass containing the most abundant 
isotope for each element in the molecule is used for the ESI-MS scan and CID experiments, 
while the most abundant mass for each of the complexes is used for the LC-ESI-MS/MS 
experiments. 
 
The positive ion mass spectra obtained from a 5-fold dilution of an 1 mM aqueous solution 
of cisplatin kept at 37°C for 0 and 72 h, respectively, are given in Figure 2a and 2b. No 
significant ions were found below m/z 200, above m/z 900 or between m/z 350 - 500 and 
m/z 650 - 800. Therefore, the full scan mass spectra in the mass range of m/z 200 - 900 
(Figure 2a and Figure 2b) and expanded spectra in the mass range of m/z 220 - 340 (Figure 
2c), m/z 510 - 640 (Figure 2d), and m/z 820 - 880 (Figure 2e) were presented. Electrospray of 
the fresh solution (0 h) of cisplatin gives most abundant [M+NH4]
+ (m/z 317.0), [M+Na]+ (m/z 
322.0) ions, and abundant [M+K]+ (m/z 338.0), [2M+NH4]
+ (m/z 616.0), [2M+Na]+ (m/z 621.0) 
ions (Figure 2a), while no protonation of parent complex is observed. A variety of 
supplemental ions were observed in the mass spectra of the hydrolyzed solution (72 h) of 
cisplatin (Figure 2b).These ions correspond to newly formed mono-, di-, and trimeric species. 
The signal of the base peak at m/z 283.0 in this spectrum is beyond the MS maximum 
response (1.34*e8). An additional scan for this specie, was acquired from a 20-fold dilution of 
the hydrolysis solution, giving a response of 1.17*e8. In order to obtain the actual relative 
abundances of other species observed in Figure 2b, the theoretical response of the base 
peak in Figure 2b (5-fold dilution) is calculated by multiplying the non-saturated response for 
the 20-fold dilution base peak (1.17*e8)  by the dilution ratio (20 / 5). The thus obtained base 
peak intensity for the spectrum can then be used as the basis for the relative abundance 
calculations. This assumes a linear MS response. Next, a series of CID experiments at varying 
collision energies were undertaken to elucidate the structures. The MS/MS spectra were 
documented in Figures S1 - 20. Based on the information of the charge states, molecular 
masses, isotope distribution patterns, and fragmentation pathways obtained from ESI-MS 
and CID spectra, the structures of the observed ions were identified. An illustration of these 
structures can be found in Figure 1 and Figures S1 – 8, 11, 15, 16. Based on the number of Pt 
atoms contained in the species, the structures are divided into three subgroups, i.e. 
monomeric, dimeric, and trimeric cations. 
 
Monomeric cations 
Upon dissolving cisplatin in water, it is expected that MHC (i.e. the monoaqua complex and 
monohydroxo complex) and DHC (i.e. the diaqua complex, monohydroxylated mono aqua 
complex, and dihydroxylated complex) are formed. The presence of MHC in our solution was 
supported by the ions at m/z 281 - 287 and 303 - 307, which corresponded to the monoaqua 
complex and Na-adduct of the monohydroxo complex, respectively. Moreover, the ions (m/z 
263 - 267) of the monohydroxylated mono aqua complex and the dihydroxylated complex 
were detected, while a doubly charged [M]2+ ion (m/z 132) of the diaqua complex was not 
detected.  
 
It should be noted that the monoaqua complex ([M]+, m/z 282.0) suffers from in-source 
fragmentation when the cone voltage exceeds 40 V, giving fragmentation ions [M-H2O]
+ (m/z 
264.0) and [M-H2O-HCl]
+ (m/z 228.0). Similar to MHC, DHC is also quite sensitive to the cone 
voltage, giving fragmentation ions [M-H2O]
+ (m/z 246.0) and [M-2H2O]
+ (m/z 228.0). 
Furthermore, this ion specie suffers from the interferences of in-source fragmentation ions 
[M-H2O]
+ (m/z 263 - 267) of MHC. Therefore, careful tuning of the cone voltage is crucial for 
detecting DHC. In the present study, the cone voltage could not exceed 25 V to avoid in-
source fragmentation of DHC and to obtain the authentic isotopic pattern. This is likely the 
reason why the dihydrated complex was not observed in a previous series of hydrolysis 
investigations of  Pd(en)Br2
[28], Pd(en)Cl2
[5], and Pt(en)Cl2
[7] (en: ethylenediamine) in which a 
high cone voltage was used.   
 
Two molecular ions at m/z 291 - 295 and m/z 273 - 277 were identified as Pt+(NH3)2(N2)Cl 
and Pt+(NH3)2(N2)(OH). These species result from the clustering of ion-source fragmentation 
ions [M-H2O]
+ of MHC and DHC, respectively, with desolvation gas N2. The Pt
+(NH3)2(N2)Cl ion 
has been confirmed in a recent hydrolysis investigation of cisplatin using high-resolution 





Dimer 4 ([M]+, m/z 563.0):  The ions in the mass spectrum which clustered at m/z 561 - 569, 
having a relative abundance of 6.8 %, was interpreted as the Pt(NH3)2Cl2 · Pt
+(NH3)2Cl dimeric 
complex. The overall single positive charge is the result of the loss of a chloride ion in the 
complex. It is interesting to see that only moderately abundant Pt(NH3)2Cl2 · Pt
+(NH3)2Cl was 
found in our ESI-MS study, while the similar dimeric species M(en)X2 · M
+(en)X (M: Pd, Pt, X: 
Cl, Br) are observed as the base peak ions in the previous ESI-MS hydrolysis investigations[5, 7, 
28]. This is most probably caused by the different pH in the hydrolysis solution since the 
species observed are quite pH dependent.  
 
When the ion [M]+ at m/z 563.0 is subjected to CID, the fragment ions at m/z 546.0 and m/z 
529.0 were produced by sequential loss of one, respectively two NH3 groups (Figure S16). 
The fragmentation ions at m/z 510 and 508 correspond to  the neutral loss of HCl from m/z 
546.0. Further fragmentation results in the loss of Pt and chloride atoms containing groups, 
yielding product ions clustering at m/z 263.0, m/z 246.0, m/z 227.0, m/z 210.0, which were 
already discussed in the above monomeric cations section (for reference, see the 
supplementary materials). The dimeric complex did not break apart into its monomer 
subunit Pt+(NH3)2Cl
 during initial CID experiments, contrary to what we would expect for a 
non-covalently bound complex. Instead, the sequential loss of NH3 and HCl occurred, 




The observed Pt(NH3)2Cl2 · Pt
+(NH3)2Cl
 ion is likely to be formed from the reaction of the 
neutral Pt(NH3)2Cl2 with its monoaqua complex Pt(NH3)2Cl(H2O)
+. The ESI-MS properties of 
cisplatin and its hydrolysis products can also be investigated by looking at its analogs (e.g. 
Pd(en)Br2, Pd(en)Cl2, Pt(en)Cl2), which are expected to hydrolyze in an analogous way as 
cisplatin. The density functional theory (DFT) calculations used in the previous hydrolysis 
study of Pt(en)Cl2 demonstrated that the clustering reaction of parent drug and its 
monoaqua complex is favored in the gas phase and only slightly endergonic in solution, 
suggesting that the formation of this dimeric species is possible both in solution and during 
the ESI-MS process[7]. An aggregation formation pathway is also proposed by the same 
authors[7]. That is, a dimeric structure clustered from two intact parent molecules is first 
formed, then a chloride is lost to yield the observed ion. This pathway is theoretically 
possible in solution, while it is predicted to be highly endergonic in the gas phase. Therefore, 
the formation mechanism for this dimer is still unclear when only the ESI-MS and DFT 
calculations were employed, requiring further investigations using LC-MS/MS (see further 
on).  
 
Dimer 3 ([M]+, m/z 545.0):  The observation of a complex with the most abundant ion at m/z 
545.0 and a relative abundance of 8.6 % is consistent with the Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl 
ion (Figure 2b). CID of the Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl ion at m/z 545.0 (Figure S15) leads to 
three fragment ions at m/z 528.0, 510.0 and 493.0 by sequential loss of NH3, H2O and NH3. 
Further fragmentation of m/z 493.0 yields the ions at m/z 457.0 and 455.0, 421.0 and 419.0, 
as well as 404 and 402 via successive loss of two HCl and one NH3 molecules. Finally, the ion 
at m/z 404 and 402 produces the similar cluster of ions at m/z 263.0, m/z 246.0, m/z 227.0, 
m/z 210.0 as dimer 4 due to the loss of Pt and Cl containing species.   
 
A. Yoshikawa et al. [7] explained the formation of the Pt(en)(OH)Cl · Pt+(en)Cl ion via the 
clustering of the neutral [M-HCl] (M: Pt(en)Cl2) ion with the [M-Cl+H2O]
+ ion, followed by 
proton transfer from the bridging H2O group to the deprotonated amino group. Instead, we 
believe that the Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl ion is formed from clustering of the 
monohydroxo complex (Pt(NH3)2Cl(OH)) and the monoaqua complex (Pt(NH3)2Cl(H2O)
+) via a 
hydroxo-bridging interaction by the loss of H2O.   
 
Dimer 2 ([M]+, m/z 527.0): The ions starting at m/z 525 - 534 with a relative abundance of 1.9 
% were attributed to an overlay of the ions of dimer 2 ((Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH),m/z 
527.0) and an in-source fragment ion [M-NH3]
+ (Pt(NH3)2(OH)Cl · Pt
+(NH3)Cl, m/z 528.0) of 
dimer 3.  The theoretical isotope distribution with corresponding intensities for the 
Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH) ion starts from m/z 525 (35.5 %) to 533 (5.36 %) with the 
most abundant mass being m/z 527 (100 %). The pattern starting from m/z 526 (32.4 %) to 
534 (11.3 %) with the most abundant mass at m/z 528 (100 %) is thought to originate from 
the in-source fragment ion Pt(NH3)2(OH)Cl · Pt
+(NH3)Cl. The relative peak intensities of the 
two overlapping complexes (m/z 525 - 534) was influenced by the cone voltage (Figure S9). 
This provided us with a  means to distinguish between these two ions. At a cone voltage of 
20 V, when only weak in-source fragmentation would occur, the most abundant ion of the 
cluster ions (m/z 525 - 534) was at m/z 527.0 with an isotope pattern of 37.1: 70.6: 100 at 
m/z 525 - 527. This corresponds to the Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH) ion containing two Pt 
and one Cl atoms. At a cone voltage of 45 V, the most abundant ion became m/z 528.0 with 
a clustering pattern of 40.1: 71.4: 100: 89.3: 81.0: 49.9: 36.7: 13.6: 10.6 at m/z 526 - 534. 
This pattern is in excellent agreement with the theoretical values for an ion containing two 
Pt and two Cl elements. The increase in the signals of the ion at m/z 528.0 and decrease in 
the response of the dimer 3 at high cone voltages indicated that the Pt(NH3)2(OH)Cl · 
Pt+(NH3)Cl ion probably results from in-source fragmentation of dimer 3.  
 
Further support for this hypothesis comes from a series of CID experiments at m/z 525 and 
527 at a cone voltage of 20 V (Figures S10 and S12), and at m/z 525, 528, and 534 at a cone 
voltage of 45 V (Figures S11, S13, and S14). The ions at m/z 525 (cone voltage: 20 and 45 V) 
and 527 (cone voltage: 20 V) demonstrated identical fragment patterns via the loss of H2O, 
NH3 and HCl (Figures S10 and S11). This confirmed the presence of two Pt and one Cl 
elements in the proposed structure: Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH). When the ions at m/z 
528 and 534 (cone voltage: 45 V) undergo CID (Figures S13 and S14), a similar fragmentation 
pattern was observed as discussed above for dimer 3. This offers the confidence for ascribing 
the Pt(NH3)2(OH)Cl · Pt
+(NH3)Cl ion to the in-source fragment ion of dimer 3.  
 
The formation of dimer 2 (Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH)) can also be explained by assuming 
the hydroxo-bridging of the monohydroxo complex (Pt(NH3)2Cl(OH)) and the 
monohydroxylated mono aqua complex (Pt(NH3)2(OH)(H2O)
+) via the loss of H2O. This is 
supported by the presence of these two hydrolyzed species.  
 
Dimer 5 ([M+Na]+, m/z 603.0): The cation observed at m/z 601 - 609 with a relative 
abundance of 1.8 % is assumed to be sodium adduct of Pt(NH3)2Cl(OH)
 · Pt(NH3)2Cl2 complex  
resulting from clustering of the monohydroxo complex (Pt(NH3)2Cl(OH)) and intact cisplatin 
via non-covalent bonds. The weak nature of this interaction is corroborated by the CID 
where the Pt(NH3)2Cl(OH)Na
+ ion was easily formed with 100 % relative abundance, through 
the loss of neutral cisplatin (Figure S18).  
 
Trimeric cations 
Clustering of neutral cisplatin with dimer 2, 3, and 4 (m/z 826.0, 844.0, and 862.0) resulted in 
three extremely low abundant (0.15 - 0.2 %) ion clusters at m/z 823 - 833, 841 - 852 and 859 
- 871. These are assumed to be the Pt(NH3)2Cl2 · Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH), Pt(NH3)2Cl2 · 
Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl, and Pt(NH3)2Cl2 · Pt(NH3)2Cl2 · Pt
+(NH3)2Cl ions. They are likely to 
be formed via non covalent interactions between cisplatin and dimer 2, 3, and 4, 
respectively. Although CID experiments for these clusters were not performed due to the 
lack of sensitivity, the non-covalent bound properties of these complexes can be learned 
from the reported trimetallic cations (i.e. [3M-HCl-Cl+H2O]
+ and [3M-Cl]+) of Pt(en)Cl2
[7].  
 
As demonstrated in the above analysis, various monomeric cations of cisplatin, MHC, and 
DHC were detected. This is in line with previous hydrolysis studies of cisplatin[10, 18]. 
Nevertheless, we discovered a number of previously unreported monomeric cations such as 
the Na-adduct of the monohydroxo complex and Pt+(NH3)2(N2)(OH). Furthermore, the 
previously reported hydroxo-bridged dimer[10] (dimer 1) of the dihydrated complex, as well 
as the previously unreported [2M+NH4]
+ , [2M+Na]+ (both of cisplatin) (Figures S19 and S20) 
and [2M+Na]+ (of the monohydroxo complex) ions (Figure S17) were also observed in our 
study. Besides these previously unreported monomeric cations, more interestingly, a variety 
of unreported di- and trimeric cations were detected in our hydrolysis study.  
 
LC-ESI-MS/MS experiments 
As discussed above, the formation mechanisms of the observed (dimeric) complexes cannot 
be fully elucidated via ESI-MS infusion studies alone. Thus, LC-ESI-MS/MS (See supporting 
documents for key comments on the LC-MS/MS) was used to further confirm our findings 
and elucidate how and when the species are formed (i.e. in solution or in the gas phase or 
both). The typical chromatogram obtained from a 40-fold dilution of a sample of cisplatin 
which was incubated at 37°C for 55 h is shown in Figure 3. The peak areas as a function of 
time for cisplatin and its hydrolyzed species are shown in Figure 4.  
 
The peak eluting at 1.78 min in Figure 3 (a) is intact cisplatin and the small peak at 1.37 min 
is assumed to be transplatin since it shows similar MS/MS behaviour as cisplatin. In our 
study, cisplatin undergoes a hydrolytic degradation to 28.8% of its initial value after 24 h. 
This finding is consistent with earlier literature reports[10, 29, 30]. It was also reported that the 
cis-trans isomerization of cisplatin occurs in aqueous solutions and is increased at elevated 
temperatures[31]. As shown in Figure 4, transplatin is formed gradually when dissolving 
cisplatin in water, reaching a plateau after 24 h. We calculated that approximately 7.6 % of 
initial cisplatin is converted to transplatin after 24 h. This was based on the assumption that 
the MS/MS response is similar between cisplatin and transplatin.  
 
The presence of MHC is observed from the peak eluting at 1.94 min in Figure 3 (c). The peak 
area of MHC increases over 24 h along with the degradation of cisplatin. As seen from Figure 
4, it is the most abundant hydrolysis product. As illustrated in Figure S21 (a), DHC presented 
itself as a broad and tailing peak at 2.9 - 4.4 min, Adjusting the elution conditions (e.g. pH of 
the mobile phase, and gradient settings) did not significantly improve the peak shape. The 
dihydrated dimer gave rise to a minor peak at 3.75 min (Figure S21 (b)). In an undiluted 
hydrolysis solution nevertheless, it showed an abundant intensity in the corresponding ESI-
MS spectrum. This indicates that the dihydrated dimer probably decomposes readily in the 
applied (acidic) elution conditions. This is conformed in earlier work by Cui[10] and Berners-
Price[32].  
 
Dimer 4, shown in Figure 3 (b), eluting simultaneously with cisplatin, was gradually formed 
over 24 h. Afterwards, its  concentration remained stable for the remainder of the 
incubation time interval. As discussed above, dimer 4 can be formed through the reaction of 
neutral cisplatin with its monoaqua complex or through an aggregation pathway. The 
aggregation pathway, however, is not supported by our experimental results since an 
increasing formation leveling out from 7 h onwards was observed for dimer 4. If aggregation 
would occur in solution, an initial increase followed by a decrease is expected for dimer 4 
due to the decreasing cisplatin concentrations. A similar, decreasing concentration-time 
pattern comparable to cisplatin is also expected for dimer 4 when the aggregation happens 
in the gas phase.  The formation of dimer 4 in the gas phase via a clustering reaction is 
equally not supported by our results since cisplatin and its monoaqua complex are well 
separated and would therefore not exist simultaneously in the gas phase. Our analysis 
indicated that dimer 4 is most likely to be formed in solution via a clustering reaction 
between cisplatin with its monoaqua complex.  
 
For dimer 3, two peaks were found. As seen from Figure 3 (d), one peak eluted at 1.93 min 
(peak 1) and another at 2.60 min (peak 2). Peak 1 always demonstrated an identical 
retention with MHC, even under various elution conditions. Furthermore, the peak area 
ratios of MHC to peak 1 are stable throughout the whole incubation time. Therefore, we 
assume that peak 1 is formed in the gas phase via the clustering of the monohydroxo 
complex and the monoaqua complex. Peak 2, however, is regarded as the authentic form of 
dimer 3 and is formed in solution since it is chromatographically separated from MHC. Its 
formation time profile is presented in Figure 4. Our results demonstrate that dimer 3 can be 
formed both in the gas phase and in solution via clustering of the monohydroxo and the 
monoaqua complexes.  
 
The specific transition 528.0 > 264.0 of the observed Pt(NH3)(OH) · Pt
+(NH3)2Cl ion shows two 
peaks in Figure 3 (e), labeled as peak 3 and peak 4. Their retention times are consistent with 
peak 1 and peak 2 of dimer 3. The peak area ratios of peak 1 to peak 3 and  peak 2 to peak 4 
are identical and behave similar over the whole 55 h incubation time interval, indicating that 
this species is an in-source fragment of dimer 3, confirming our  ESI-MS observations 
regarding this ion.  
 
Similarly, the peak shown in Figure 3 (f) is presumed to be dimer 2. Although it elutes at the 
same retention time as MHC, the peak area ratios of MHC to dimer 2 are different up until 
the moment when the hydrolysis equilibrium is reached. Therefore, the dimer 2 is more 
likely to be formed in the solution via the reaction of the monohydroxo  and 
monohydroxylated mono aqua complexes. This can also be confirmed from its extremely low 
abundance since the monohydroxylated mono aqua complex is found in very low contents.  
 
The weakly bound dimer 5 showed a poorly shaped peak centered at 1.80 min, with a  
baseline ranging from 1.60 min to 2.1 min (Figure S21 (c)). The formation pathway for dimer 
5 is unclear since it is almost undetectable after the 40-fold dilution of the hydrolysis 
solution.   
 
The LC-ESI-MS/MS data confirmed that there were not only cisplatin and its mono- and di 
hydrated complexes in the hydrolysis solution, but also their clustering dimers (dimer 1 - 4). 
It is worth noting that in our study, three unreported dimers (dimer 2 - 4), adding up to 
17.3% relative abundance, were detected in the hydrolysis solution. These dimers were in 
equilibrium with monomeric species. In a previous hydrolysis study[10], the mono- and 
dihydrated species, and dihydrated dimer species (dimer 1) were found using the same 
initial concentration of cisplatin. The three unidentified species from this study, located at 
m/z 500 - 580, are consistent with dimer 2 - 4 which were observed in our study. Based on 
these newly found dimers in hydrolyzed solution, a renewed equilibrium system for cisplatin 
is presented in Figure 1, previously unreported.  
 
Conclusions 
Our ESI-MS study identified a number of previously unreported Pt-containing complexes. 
These correspond to mono-, di-, and trimeric complexes of cisplatin, of which the most 
abundant complex is the monohydrate. The structures of the complexes were elucidated by 
combining full scan MS data, data on expected/observed isotope patterns, MS/MS and LC-
ESI-MS/MS experiments. The strongly bound Pt(NH3)2Cl2 · Pt
+(NH3)2Cl and Pt(NH3)2(OH)Cl · 
Pt+(NH3)2(OH) dimeric species are believed to be the only ones formed in solution, whereas 
the Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl ion can be formed both in solution and during the ESI 
process. The observed Pt+(NH3)2(N2)Cl, Pt
+(NH3)2(N2)(OH), and Pt(NH3)2(OH)Cl · Pt
+(NH3)Cl 
ions were qualified as cold clusters. The formation of the Pt(NH3)2Cl2 · Pt
+(NH3)2Cl, 
Pt(NH3)2(OH)Cl · Pt
+(NH3)2Cl and Pt(NH3)2(OH)Cl · Pt
+(NH3)2(OH) bimetallic cations is 
hypothesized to originate via clustering reactions of cisplatin and its mono- and dihydrated 
species. At the same time, three weakly bound trimetallic ions were observed, arising from 
ion-molecule interactions between three bimetallic cations and cisplatin. Our study of the 
hydrolysis kinetics of cisplatin has revealed a rich and complicated aqueous chemistry and 
based on these results a new equilibrium system of cisplatin in H2O is proposed.  
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Table 1. Detection parameters for the different species under study. 
Species Cone voltage (V) Collision voltage (kV) MRM transitions 
Dimer 1 25,0 12,0 245.76 > 228.24 
DHC 20,0 14,0 264.04 > 227.99 
MHC 25,0 8,0 283.01 > 265.00 
Cisplatin 25,0 14,0 318.11 > 265.00      
Dimer 2 20,0 18,0 527.01 > 473.96 
Pt(NH3)(OH) · Pt
+(NH3)2Cl ion 45,0 25,0 528.01 > 264.01 
Dimer 3 20,0 10,0 544.97 > 527.95 
















Figure 1 The previously reported (marked by the dashed line) and updated hydrolysis 



















Figure 2 ESI-MS spectra of a 5-fold dilution of an 1 mM aqueous solution of cisplatin 
incubated at 37°C for 0 h (a) and 72 h (b). (c) Expanded spectrum in the range of m/z 220 - 
340. (d) Expanded spectrum in the range of m/z 510 - 640. (e) Expanded spectrum in the 
range of m/z 820 - 880. Inserts: experimental (lines) and theoretically calculated (bars) 





Figure 3 Representative LC-ESI-MS/MS chromatograms of cisplatin and its hydrolysis 
complexes obtained from a 40-fold dilution of a solution of 1 mM (initial) cisplatin, incubated 
for 55 h at 37°C. (a) LC-ESI-MS chromatograms of cisplatin (1.78 min) and transplatin (1.37 
min). (b) LC-ESI-MS chromatogram of dimer 4 (1.78 min). (c) LC-ESI-MS chromatogram of 
MHC (1.94 min). (d) LC-ESI-MS chromatogram of dimer 3: peak 1 (1.93 min, in source 
formation via clustering of the monohydroxo complex and the monoaqua complex) and peak 
2 (2.60 min, formation in solution via clustering of the monohydroxo and the monoaqua 
complexes). (e) LC-ESI-MS chromatogram of the Pt(NH3)(OH) · Pt
+(NH3)2Cl ion, an in-source 




Figure 4 Time resolved patterns of mean peak areas and their 95% confidence intervals of 
cisplatin and its hydrolysis species obtained from a 40-fold dilution of a solution of 1 mM 
(initial) cisplatin, incubated for 55 h at 37°C. 
 
 
 
